{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Podzamczer D"],"funding":["SPANISH AIDS Research Network","ISCIII- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional"],"pagination":["ofab595"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8883591"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(3)"],"pubmed_abstract":["Background
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF and combination therapy based on integrase inhibitors in antiretroviral-naive patients are lacking.Methods
Adult (>18 years old) human immunodeficiency virus-infected antiretroviral-naive patients (HLA-B∗5701 negative and hepatitis B virus negative), with viral load (VL) ≥500 c/mL, were centrally randomized to initiate D/C/F/TAF or dolutegravir/abacavir/lamivudine (DTG/3TC/ABC) after stratifying by VL and CD4 count. Clinical and analytical assessments were performed at weeks 0, 4, 12, 24, and 48. The primary endpoint was V"],"journal":["Open forum infectious diseases"],"pubmed_title":["Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)."],"pmcid":["PMC8883591"],"funding_grant_id":["RD16/0025/0001"],"pubmed_authors":["Knobel H","Podzamczer D","Fanjul F","Bernal E","Sanz J","Gomez C","Mican R","Rivero A","Masia M","Vinuesa D","Llibre JM","Montero M","Payeras A","Domingo P","Ribera E","Fernandez G","Portilla J","Macias J","Troya J","Tiraboschi J","Caicedo A","Inciarte A","Moreno S","Estrada V","Vivancos MJ","Navarro-Alcaraz A","Castro A","Martinez E","Morano L"],"additional_accession":[]},"is_claimable":false,"name":"Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).","description":"Background
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF and combination therapy based on integrase inhibitors in antiretroviral-naive patients are lacking.Methods
Adult (>18 years old) human immunodeficiency virus-infected antiretroviral-naive patients (HLA-B∗5701 negative and hepatitis B virus negative), with viral load (VL) ≥500 c/mL, were centrally randomized to initiate D/C/F/TAF or dolutegravir/abacavir/lamivudine (DTG/3TC/ABC) after stratifying by VL and CD4 count. Clinical and analytical assessments were performed at weeks 0, 4, 12, 24, and 48. The primary endpoint was V","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T07:55:11.378Z","creation":"2025-04-04T07:55:11.378Z"},"accession":"S-EPMC8883591","cross_references":{"pubmed":["35237700"],"doi":["10.1093/ofid/ofab595"]}}